First treatment for dementia of Parkinson's disease.
D003704:Dementia / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine; D014481:United States; D014486:United States Food and Drug Administration
D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine